Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 71335-0416

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 71335-0416). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig-1 (Donepezil Figure 1)

A line graph showing ADAS-cog score changes from baseline over 24 weeks of drug treatment comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The vertical axis shows mean change with standard error, indicating clinical improvement or decline. Donepezil groups show sustained improvement, while placebo shows clinical decline over time.*

FDA Label Image

Fig-10 (Donepezil Figure 10)

A cumulative percentage line graph comparing Donepezil Hydrochloride 10 mg/day to placebo. The x-axis represents ADCS-ADL change from baseline, ranging from 20 to -20, and the y-axis shows the cumulative percentage of patients from 0% to 100%. Donepezil shows a higher cumulative percentage of patients at lower ADCS-ADL change values compared to placebo, indicating a difference in patient response over the range observed.*

FDA Label Image

Fig-11 (Donepezil Figure 11)

A line graph showing the SIB (Severe Impairment Battery) change from baseline over 24 weeks of drug treatment with Donepezil Hydrochloride at doses of 10 mg/day and 23 mg/day. The y-axis represents the mean change from baseline with standard error, ranging from -3 to 5, indicating clinical decline below baseline and clinical improvement above. The 23 mg/day group shows greater clinical improvement over time compared to the 10 mg/day group.*

FDA Label Image

Fig-12 (Donepezil Figure 12)

A cumulative percentage plot showing the effect of Donepezil Hydrochloride at doses of 10 mg/day and 23 mg/day on SIB (Severe Impairment Battery) change from baseline in patients. The X-axis represents SIB change from baseline ranging from +50 to -60, while the Y-axis shows the cumulative percentage of patients from 0 to 100%. Two trend lines compare the two dosage strengths.*

FDA Label Image

Fig-13 (Donepezil Figure 13)

A bar chart comparing the percentage of patients by CIBIC-plus Rating categories for Donepezil Hydrochloride dosed at 23 mg/day and 10 mg/day. The x-axis shows rating categories from Markedly Improved to Markedly Worse, and the y-axis shows percentage of patients from 0 to 50%. Bars for both doses are shown side by side within each rating category.*

FDA Label Image

Fig-2 (Donepezil Figure 2)

A cumulative percentage graph showing patient response to Donepezil Hydrochloride 10 mg, 5 mg, and placebo. The x-axis represents change from baseline in ADAS-cog scores, ranging from -15 to 15, while the y-axis shows cumulative percentage of patients from 0 to 100%. Curves depict the proportion of patients achieving 7-point, 4-point improvements, or no change, comparing Donepezil 10 mg, 5 mg doses, and placebo groups, with an accompanying table summarizing percentages at key change points.*

FDA Label Image

Fig-3 (Donepezil Figure 3)

A bar chart depicting the percentage of patients by CIBIC-plus rating categories for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The x-axis shows ratings from Markedly Improved to Markedly Worse, and the y-axis shows percentage of patients. Different bars represent the three groups, illustrating patient distribution across the ratings.*

FDA Label Image

Fig-4 (Donepezil Figure 4)

Line graph depicting the ADAS-cog mean change from baseline over weeks of drug treatment comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The vertical axis shows cognitive change (clinical improvement to decline), and the horizontal axis plots weeks. Both doses of Donepezil show clinical improvement, while placebo shows clinical decline by week 15.*

FDA Label Image

Fig-5 (Donepezil Figure 5)

A cumulative percentage of patients line graph comparing treatment groups Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The x-axis shows change from baseline scores, and the y-axis shows cumulative patient percentages. Vertical lines mark 7 points, 4 points, and no change thresholds. An inset table summarizes percentage of patients by treatment group achieving respective changes in ADAS-cog scores.*

FDA Label Image

Fig-6 (Donepezil Figure 6)

A bar chart depicting the percentage of patients by CIBIC-plus Rating categories: Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse. The chart compares three groups: Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and Placebo, with percentage values shown on the vertical axis.*

FDA Label Image

Fig-7 (Donepezil Figure 7)

A line graph depicting SIB (Severe Impairment Battery) change from baseline mean over 6 months of drug treatment. It compares Donepezil Hydrochloride 10 mg/day and placebo groups. The vertical axis measures change from baseline, with direction arrows indicating clinical improvement above and clinical decline below baseline. Donepezil shows clinical improvement peaking at 3 months, while placebo trends towards decline.*

FDA Label Image

Fig-8 (Donepezil Figure 8)

Cumulative percentage of patients graph showing SIB (Severe Impairment Battery) change from baseline. The plot compares two groups: Donepezil Hydrochloride 10 mg/day and placebo, with cumulative percentage of patients on the y-axis and SIB change from baseline on the x-axis. The Donepezil group shows a higher cumulative response compared to placebo across the SIB change values.*

FDA Label Image

Fig-9 (Donepezil Figure 9)

A line graph showing ADCS-ADL change from baseline over 6 months of treatment comparing Donepezil Hydrochloride 10 mg/day and placebo. The vertical axis represents mean change ± SE from baseline, ranging from -4 to 4, indicating clinical improvement or decline. The horizontal axis represents months of drug treatment (0, 3, and 6 months). Data points with error bars show Donepezil Hydrochloride and placebo decline over time, with placebo showing a steeper decline.*

FDA Label Image

Str (Donepezil Str)

FDA Label Image

Label Image (Lbl713350416)

Donepezil Hydrochloride 10 mg film-coated tablet packaging label by Bryant Ranch Prepack. The label includes storage instructions to keep the tablets at room temperature between 20-25°C (68-77°F). It references comparison to Aricept 10 mg tablets by Torrent Pharmaceuticals Limited and indicates a quantity of 30 tablets. The label features a lot number, barcode, and NDC 71335-0416.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.